We are live on
!
Find out more
AG
Artal Group Portfolio holdings
AUM
$1.01B
1-Year Est. Return
29.84%
This Fund
S&P 500
This Quarter
Est. Return
+29.93%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.38B
AUM Growth
-$1.54B
(-39%)
Cap. Flow
-$2.13B
Cap. Flow
% of AUM
-89.3%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
112
New
–
Increased
–
Reduced
2
Closed
110
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CAVA Group
CAVA
|
+$610M |
| 2 |
Scholar Rock
SRRK
|
+$93.8M |
| 3 |
Kymera Therapeutics
KYMR
|
+$89.7M |
| 4 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$86.1M |
| 5 |
Arrowhead Research
ARWR
|
+$82.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 91.02% |
| 2 | Healthcare | 8.98% |
| 3 | Communication Services | 0% |
| 4 | Real Estate | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Dell
DELL
$239B
| – | – |
-1,000
| Closed | -$138K |
|
27
dLocal
DLO
$4.29B
| – | – |
-10,482
| Closed | -$84.8K |
|
28
Denali Therapeutics
DNLI
$3.79B
| – | – |
-502,899
| Closed | -$11.7M |
|
29
Dynatrace
DT
$12.7B
| – | – |
-109,000
| Closed | -$4.88M |
|
30
Dyne Therapeutics
DYN
$4.15B
| – | – |
-1,516,960
| Closed | -$53.5M |
|
31
New Oriental
EDU
$9.32B
| – | – |
-12,500
| Closed | -$972K |
|
|
ELEV
32
DELISTED
Elevation Oncology
ELEV
| – | – |
-1,013,015
| Closed | -$2.74M |
|
33
Erasca
ERAS
$6.15B
| – | – |
-9,630,810
| Closed | -$22.7M |
|
34
Edgewise Therapeutics
EWTX
$4.28B
| – | – |
-811,718
| Closed | -$14.6M |
|
35
Fate Therapeutics
FATE
$275M
| – | – |
-1,032,500
| Closed | -$3.39M |
|
36
Foghorn Therapeutics
FHTX
$278M
| – | – |
-720,720
| Closed | -$4.14M |
|
37
JFrog
FROG
$8.88B
| – | – |
-25,000
| Closed | -$939K |
|
|
GBIO
38
DELISTED
Generation Bio
GBIO
| – | – |
-283,059
| Closed | -$7.98M |
|
|
CBIO
39
Crescent Biopharma
CBIO
$546M
| – | – |
-85,891
| Closed | -$2.42M |
|
40
Alphabet (Google) Class A
GOOGL
$4.12T
| – | – |
-7,000
| Closed | -$1.28M |
|
41
CALL
Gossamer Bio
GOSS
$101M
| – | – |
-207,000
| Closed | -$186K |
|
|
42
Gossamer Bio
GOSS
$101M
| – | – |
-13,308,968
| Closed | -$12M |
|
|
HOOK
43
DELISTED
HOOKIPA Pharma
HOOK
| – | – |
-566,641
| Closed | -$3.35M |
|
|
IGMS
44
DELISTED
IGM Biosciences
IGMS
| – | – |
-3,330,422
| Closed | -$22.9M |
|
45
Intel
INTC
$413B
| – | – |
-25,000
| Closed | -$774K |
|
46
Intapp
INTA
$2.44B
| – | – |
-13,000
| Closed | -$477K |
|
47
Iovance Biotherapeutics
IOVA
$2.04B
| – | – |
-1,011,500
| Closed | -$8.11M |
|
48
Ironwood Pharmaceuticals
IRWD
$586M
| – | – |
-110,532
| Closed | -$721K |
|
49
Janux Therapeutics
JANX
$912M
| – | – |
-203,000
| Closed | -$8.5M |
|
|
KRON
50
DELISTED
Kronos Bio
KRON
| – | – |
-842,954
| Closed | -$1.05M |
|
Similar funds
BCM
GA
EPAM
WA
CT
AH
PIM
MAM
Artal Group's Q3 2024 Portfolio in Review
As of Q3 2024, Artal Group held 112 positions worth $2.38B, down 39% from $3.92B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Artal Group withdrew a net $2.13B in Q3 2024, closing 110 positions and reducing 2 holdings. Its most notable exit was Scholar Rock, an estimated $93.8M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 91% of assets, up from 56% a quarter earlier, followed by Healthcare and Communication Services.
- Artal Group's biggest Q3 2024 reduction was CAVA Group, cutting an estimated $610M.
- Artal Group fully exited Scholar Rock in Q3 2024, selling an estimated $93.8M.
- Artal Group's ten largest holdings make up 100% of its $2.38B portfolio in Q3 2024.
- Artal Group opened 0 new positions and closed 110 in Q3 2024.
- Artal Group's portfolio value fell 39% quarter-over-quarter to $2.38B.
Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.